Application of synergistic β-lactamase inhibitors and antibiotics in the treatment of wounds infected by superbugs

Arabian Journal of Chemistry

Guojun Wang¹  Jing Su²  Shizhong Zhang³  Xiao Chen³  Mengkao Li³  Jie yang⁴  Zekun Wang⁴  Weiyun Wang⁴  Xiaoyuan Ding⁴  Dongdong Sun⁴  Jingyuan Wang⁴ 

[1] Corresponding authors.;Department of Geriatric Cardiovascular, Taian City Central Hospital, Taian, Shandong 271000, China;Department of Neurosurgery, Taian City Central Hospital, Taian, Shandong 271000, China;School of Life Sciences, Anhui Agricultural University, Hefei 230036, Anhui, P.R. China;

关键词: Prussian blue;    β-lactamase inhibitor;    Amoxicillin;    Antibacterial action;    Antibiotic resistance;   

DOI  :  

来源: DOAJ

【 摘 要 】

Amoxicillin appears to be clinically drug-resistant due to the presence of β-lactamase in bacteria. Here, we designed and prepared a hollow Prussian Blue (HPB)-based therapeutic nanoplatform that was constructed by encapsulating amoxicillin into polyethyleneimine with β-lactamase inhibitor 4-carboxyphenylboronic acid (4-Cpba) decorated HPB nanoparticles (CPA NPs). The antibacterial effect of the CPA NPs on drug-resistant bacteria was observed by in vitro colony-forming unit, minimum inhibitory concentration, scanning electron microscopy, and fluorescence tests. The results show that amoxicillin effectively inhibited Escherichia coli and Staphylococcus aureus-resistant bacteria in the presence of 4-Cpba. The in vivo experimental results show that the CPA NPs exhibited a synergistic anti-infective effect in vivo, which inhibited the inflammatory response and apoptosis induced by the drug-resistant bacterial infection, and promoted wound healing in mice. The hematoxylin and eosin staining and blood biochemical experiments revealed that the acute toxicity of the material was negligible and it had good biocompatibility. Our results verify our design that CPA NPs can restore the antibacterial activity of amoxicillin.

【 授权许可】

Unknown